Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 12 2020
10 12 2020
Historique:
received:
10
08
2020
accepted:
18
11
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
21
5
2021
Statut:
epublish
Résumé
Facioscapulohumeral muscular dystrophy (FSHD) is a myopathy with prevalence of 1 in 20,000. Almost all patients affected by FSHD carry deletions of an integral number of tandem 3.3 kilobase repeats, termed D4Z4, located on chromosome 4q35. Assessment of size of D4Z4 alleles is commonly used for FSHD diagnosis. However, the extended molecular testing has expanded the spectrum of clinical phenotypes. In particular, D4Z4 alleles with 9-10 repeat have been found in healthy individuals, in subjects with FSHD or affected by other myopathies. These findings weakened the strict relationship between observed phenotypes and their underlying genotypes, complicating the interpretation of molecular findings for diagnosis and genetic counseling. In light of the wide clinical variability detected in carriers of D4Z4 alleles with 9-10 repeats, we applied a standardized methodology, the Comprehensive Clinical Evaluation Form (CCEF), to describe and characterize the phenotype of 244 individuals carrying D4Z4 alleles with 9-10 repeats (134 index cases and 110 relatives). The study shows that 54.5% of index cases display a classical FSHD phenotype with typical facial and scapular muscle weakness, whereas 20.1% present incomplete phenotype with facial weakness or scapular girdle weakness, 6.7% display minor signs such as winged scapula or hyperCKemia, without functional motor impairment, and 18.7% of index cases show more complex phenotypes with atypical clinical features. Family studies revealed that 70.9% of relatives carrying 9-10 D4Z4 reduced alleles has no motor impairment, whereas a few relatives (10.0%) display a classical FSHD phenotype. Importantly all relatives of index cases with no FSHD phenotype were healthy carriers. These data establish the low penetrance of D4Z4 alleles with 9-10 repeats. We recommend the use of CCEF for the standardized clinical assessment integrated by family studies and further molecular investigation for appropriate diagnosis and genetic counseling. Especially in presence of atypical phenotypes and/or sporadic cases with all healthy relatives is not possible to perform conclusive diagnosis of FSHD, but all these cases need further studies for a proper diagnosis, to search novel causative genetic defects or investigate environmental factors or co-morbidities that may trigger the pathogenic process. These evidences are also fundamental for the stratification of patients eligible for clinical trials. Our work reinforces the value of large genotype-phenotype studies to define criteria for clinical practice and genetic counseling in rare diseases.
Identifiants
pubmed: 33303865
doi: 10.1038/s41598-020-78578-7
pii: 10.1038/s41598-020-78578-7
pmc: PMC7730397
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21648Subventions
Organisme : Telethon
ID : GUP13012
Pays : Italy
Références
Neuromuscul Disord. 1998 Apr;8(2):126-30
pubmed: 9608567
Muscle Nerve Suppl. 1995;2:S103-9
pubmed: 7739619
Muscle Nerve. 2015 Dec;52(6):1008-12
pubmed: 25900737
J Med Genet. 2004 Jan;41(1):e12
pubmed: 14729852
Curr Mol Med. 2014;14(8):1052-1068
pubmed: 25323867
Clin Genet. 2009 Jun;75(6):550-5
pubmed: 19320656
J Neurol. 2020 Aug 19;:
pubmed: 32813049
Neuromuscul Disord. 2012 Apr;22(4):339-49
pubmed: 22357364
Eur J Neurol. 2018 Feb;25(2):356-364
pubmed: 29112784
Chin Med J (Engl). 2015 Jul 5;128(13):1707-13
pubmed: 26112708
Muscle Nerve. 2010 Aug;42(2):213-7
pubmed: 20544930
Neurology. 2003 Oct 14;61(7):909-13
pubmed: 14557558
J Med Genet. 1998 Sep;35(9):778-83
pubmed: 9733041
JAMA Netw Open. 2020 May 1;3(5):e204040
pubmed: 32356886
Neurology. 2014 Sep 16;83(12):1056-9
pubmed: 25122204
Am J Hum Genet. 2012 Apr 6;90(4):628-35
pubmed: 22482803
Muscle Nerve. 2019 Jun;59(6):711-713
pubmed: 30895627
Int J Mol Sci. 2020 Apr 10;21(7):
pubmed: 32290091
Neurology. 2000 May 23;54(10):1927-31
pubmed: 10822431
Genes (Basel). 2020 Feb 28;11(3):
pubmed: 32121044
Neurology. 2019 May 7;92(19):881-882
pubmed: 30979855
Orphanet J Rare Dis. 2015 Jan 21;10:2
pubmed: 25603992
Hum Mol Genet. 2015 Feb 1;24(3):659-69
pubmed: 25256356
Handb Clin Neurol. 2011;101:167-80
pubmed: 21496633
Neuromuscul Disord. 2017 Dec;27(12):1077-1083
pubmed: 29102079
Hum Mol Genet. 2000 Nov 22;9(19):2879-84
pubmed: 11092764
J Med Genet. 2007 Mar;44(3):215-8
pubmed: 16987949
Neurology. 1993 Feb;43(2):345-8
pubmed: 8094896
Am J Hum Genet. 2016 May 5;98(5):1020-1029
pubmed: 27153398
Neuromuscul Disord. 2017 Aug;27(8):782-790
pubmed: 28625604
Neuromuscul Disord. 2004 Jan;14(1):33-8
pubmed: 14659410
Brain. 2016 Jan;139(Pt 1):13-22
pubmed: 26667281
Neuromuscul Disord. 1991;1(4):231-4
pubmed: 1822799
Neurology. 2015 Jul 28;85(4):357-64
pubmed: 26215877
Muscle Nerve. 2010 Aug;42(2):273-5
pubmed: 20658601
Am J Med Genet. 1998 May 1;77(2):155-61
pubmed: 9605290
Ann Neurol. 1996 Jun;39(6):744-8
pubmed: 8651646
J Neurol. 2003 Aug;250(8):932-7
pubmed: 12928911
Neurology. 2015 Dec 15;85(24):2147-50
pubmed: 26561289
BMJ Open. 2016 Jan 05;6(1):e007798
pubmed: 26733561
Nat Genet. 2012 Dec;44(12):1370-4
pubmed: 23143600
Nat Genet. 1992 Sep;2(1):26-30
pubmed: 1363881
Ann Neurol. 1999 Jun;45(6):751-7
pubmed: 10360767
J Neurol. 2016 Jun;263(6):1204-14
pubmed: 27126453
JAMA Netw Open. 2020 May 1;3(5):e205004
pubmed: 32356881
Brain. 2013 Nov;136(Pt 11):3408-17
pubmed: 24030947
Pract Neurol. 2016 Jun;16(3):201-7
pubmed: 26862222
Eur J Hum Genet. 2015 Jun;23(6):808-16
pubmed: 25370034